Clinical Trial Update: aKLmRNA-mediated Protein Replacement Therapy [Phase 1]

View source ↗

Summary

A Phase 1 study of aKLmRNA-mediated Protein Replacement Therapy by Klothea Bio Inc for aging, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aging

Drugs mentioned

• aKLmRNA-mediated Protein Replacement Therapy

Snippet

Sponsor: Klothea Bio Inc | Conditions: Aging | Phase 1 | Status: NOT_YET_RECRUITING